Foley & Lardner LLP Partner Kyle Faget was quoted in the MedTech Dive article, “3 key FDA topics for medtechs in 2022,” about the October 2021 release of the FDA’s list of proposed draft and final medical device guidance documents for fiscal year 2022, including the final guidance on clinical decision support (CDS) software.
Faget said that “The risk-based approach to enforcement that FDA issued previously is not easy for [technology] developers to follow. FDA needs to provide more clarity for developers as to where the boundaries are for each one of those categories.”
Faget is co-chair of Foley’s Health Care and Life Sciences Practice Groups.
People
Related News
April 3, 2026
In the News
David Rosen Weighs in on FDA's Pharma PR Crackdown – 'Stick to the Data'
Foley & Lardner LLP partner David Rosen shared insights on the regulatory challenges pharmaceutical companies face when publicly communicating around new cancer therapies in the MM+M article, “When a podcast becomes promotion: Inside the FDA’s warning shot at ImmunityBio.”
April 2, 2026
In the News
Susan Poll Klaessy and Adrienne Walker Named Chair and Vice Chair of Foley’s Bankruptcy & Business Reorganizations Practice
Foley & Lardner LLP partner Susan Poll Klaessy was appointed chair of the firm’s global Bankruptcy & Business Reorganizations Practice Group. Partner Adrienne Walker will serve as vice chair, supporting the continued growth and strategic direction of the practice.
April 1, 2026
In the News
Foley Featured on Top 10 Sales of 2025 List by Golf Inc.
Foley & Lardner LLP advised on two transactions named among Golf Inc.’s Top 10 Sales of 2025.